Detection of tumor DNA in serum of colorectal cancer patients by Kok, J.B. de et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/25601
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
Scand J Clin Lab Invest 1997; 57: 601-604
Detection of tumour DNA in serum of colorectal 
cancer patients
J. B. DE KOK,* W, W. VAN SOLINGE,*t T. J. M. RUERS,$
R. W. H. M. ROELOFS,* G. N. P. VAN MUIJEN,§ J. L. WILLEMS* &
D. W. SWINKELS*
Departments of *Clinical Chemistry, $Surgery, and §Pathology, University Hospital Nijmegen, 
Nijmegen, tEemland Hospital, Department of Clinical Chemistry, Amersfoort, The Netherlands
de Kok JB, van Soiinge WW, Ruers TJM, Roelofs RWHM, van Muijen GNP, 
Willems JL, Swinkels DW. Detection of tumour DNA in serum of colorectal 
cancer patients. Scand J Clin Lab Invest 1997; 57: 601-604.
Circulating tumour DNA has previously been detected in serum and plasma of 
patients with lung cancer and head and neck cancer. These observations could 
potentially lead to new, specific and non-invasive tools for diagnosis, prognosis 
and follow-up in neoplastic disease, if found to be a more general phenomenon. 
To test if tumour DNA is also present in serum of patients with colorectal cancer, 
we selected 14 colorectal cancer patients with advanced disease. In seven 
patients, K-ras mutations were detected in the primary tumour, using mutant- 
specific primers for point mutations in codon 12 or 13 of the K-ras gene. All 
patients were analysed for mutant DNA in serum. Tumour-specific point 
mutations, corresponding to the K-ras mutations found in the primary tumour 
were detected in the serum of all patients but one. No mutant K-ras could be 
detected in the serum of seven patients without K-ras mutations in the primary 
tumour. These results may be useful in assessing tumour burden in patients with 
neoplastic disease. Moreover, consecutive testing of serum tumour DNA after 
surgery or chemotherapy may be used as a tumour marker for recurrent disease.
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Detection of free circulating tumour DNA in 
the serum of cancer patients offers new possi­
bilities for cancer diagnostics. Recently, sensi­
tive polymerase chain reaction (PCR)-based 
assays have been used to detect mutated tumour 
DNA sequences in the serum or plasma of 
patients with lung cancer and head and neck 
cancer [1, 2], Circulating tumour DNA was 
predominantly found in patients with advanced 
disease and in those with poor prognosis. It was 
suggested that analysis for circulating tumour
DNA might be useful in tumour staging and 
might help to identify patients at risk of tumour 
recurrence [3]. These findings are provocative 
and call for further investigation in other types 
of cancer.
Mutations in codon 12 or 13 of the K-ras gene 
occur in approximately half of all colorectal can­
cers. The detection of these mutations against a 
background of normal DNA requires highly sen­
sitive and properly validated assays. Mutant 
allele-specific amplification (MASA) by PCR uti-
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lizes the inability of Taq polymerase to elongate 
a primer when the 3' end of the primer mis­
matches the template and can therefore be used 
to selectively amplify mutated sequences [4].
In this study, patients with advanced colorec­
tal cancer were evaluated for circulating mutant 
tumour DNA in their serum. Analyses were 
based on the detection of point mutations of the 
K-ras gene in serum by MASA.
M A TE R IA LS A N D  M ETH O DS
Fourteen patients with advanced colorectal can­
cer (Dukes D) were selected.
Six 8 ¡am, formalin-fixed, paraffin-embedded 
tissue sections of the colorectal primary were 
placed in an Eppendorf tube. Six hundred 
microlitres of cell lysis solution (Puregene, 
Gentra Systems, Research Triangle Park, NC, 
USA) was added and heated for 10 min at 80°C 
in a thermomixer (Eppendorf, Hamburg, 
Germany). After centrifugation for 1 min at 
23 900xg, 10 \i\ proteinase K (20 mg/ml) 
(Boehringer Mannheim GmbH, Mannheim, 
Germany) was added and protein digestion was 
performed overnight at 55°C in a thermomixer. 
Samples were further processed according to 
the manufacturers protocol for DNA isolation 
from tissue (Puregene). DNA content was 
quantified spectrophotometrically and 5 jil, con­
taining 300 ng DNA, was used for MASA.
Blood was collected in Corvac tubes 
(Sherwood Medical, Ballymoney, N. Ireland). 
After clotting, tubes were centrifuged for 
10 min at 2000xg and serum was stored at -  
80°C until use.
DNA isolation from serum samples was per­
formed using a modified protocol for DNA  
isolation from body fluids according to the 
Puregene instructions. Briefly, 500 ¡Ú serum was 
added to a 1.5 ml Eppendorf tube containing 
500 jri cell lysis solution (Puregene), 10 fig 
poly [A] DNA (Sigma, Zwijndrecht, The 
Netherlands) and 15 jil proteinase K (20 mg/ 
ml). After protein digestion overnight at 55°C 
in a thermomixer, samples were cooled on ice. 
Two hundred microlitres of protein precipita­
tion solution was added and the samples were 
incubated on ice for 15 min after mixing. Pro­
teins were pelleted by centrifugation for 3 min 
at 23 900xg. DNA was precipitated with isopro-
panol, washed once with 70% ethanol and 
dissolved in 50 p.1 10 mM Tris-HCl (pH 8.5). 
Five microlitres was used for MASA.
MASA was performed using 20 pmol of each 
primer, 50 jiM of each dNTP, 2,5 mM MgCl2, 
1 U AmpliTaq Gold (Perkin Elmer Corpora­
tion, Foster City, CA, USA), 5 jllI IOxPCR II 
buffer (Perkin Elmer) and 5 (al sample in a total 
volume of 50 p i An initial sample dénaturation 
and polymerase activation step at 94°C for 
10 min was followed by 35 cycles of 94°C for 
1 min, 60°C for 30 s, 72°C for 45 s and a final 
extension of 10 min at 72°C. MASA forward 
primers for mutant K-ras amplification were 
identical to those used by Hasegawa et al. [4]. 
Primer #103, 5'-ACTCATGAAAATGGTCA- 
GAGAAACCTTTAT was used as antisense 
primer. PCR products (178 bp) were separated 
on a 2% agarose gel (Boehringer Mannheim 
GmbH) in 0.5xTAE buffer.
R E SU L T S
Serum and tumour tissue of 14 patients with 
colorectal cancer were analysed for point muta­
tions in codons 12 and 13 of the K-ras gene. All 
patients had systemic disease. Seven patients 
were positive for K-ras mutations in the primary 
tumour. For all positive patients but one, point 
mutations in the K-ras gene were present in the 
serum (Fig. 1), identical to the mutations 
detected in the corresponding primary tumour. 
Patients with no K-ras mutation in the tumour 
were negative for mutant K-ras in serum. To 
assess the specificity of the method, all MASA 
primers (four sets of three primers matching the 
first two nucleotides of codons 12 and 13) were 
tested on serum of these patients (data not 
shown). The method is highly specific for 
mutant K-ras and no false positive signals due 
to breakthrough of mutant-specific primers 
have been detected.
D I S C U S S I O N
In this study we demonstrate the presence of 
tumour-specific D N A  in the serum of patients 
with advanced colorectal cancer. These results, 
in a group of patients with a common type of
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